卒中后长期普拉格雷或氯吡格雷治疗期间血压水平与变异性:PRASTRO-I研究
该研究为PRASTRO-I随机双盲多中心试验的事后分析,纳入3747例非心源性卒中患者,随机接受普拉格雷3.75 mg/日或氯吡格雷75 mg/日治疗96至104周。结果显示,平均收缩压水平及访视间收缩压变异性均与复发性卒中、缺血事件及出血事件风险显著相关,且氯吡格雷与普拉格雷组间事件率无差异。
要点
- 平均收缩压每升高10 mm Hg,任何卒中风险增加(HR 1.318)。
- 收缩压连续变异每升高10 mm Hg,任何卒中风险增加(HR 3.078)。
- 高血压控制对接受普拉格雷或氯吡格雷的患者均重要。
核心结论
- 高平均收缩压水平和高访视间收缩压变异性均与长期普拉格雷或氯吡格雷治疗后复发性卒中风险显著相关。
研究设计与样本
- PRASTRO-I随机双盲多中心试验的事后分析,纳入3747例非心源性卒中患者,随机1:1接受普拉格雷3.75 mg/日或氯吡格雷75 mg/日治疗96至104周。
主要发现
- 平均收缩压每升高10 mm Hg,任何卒中风险HR 1.318(95%CI 1.094-1.583),缺血性卒中HR 1.219(95%CI 1.010-1.466),出血性卒中HR 3.247(95%CI 1.660-6.296),缺血事件HR 1.219(95%CI 1.020-1.466),出血事件HR 1.629(95%CI 1.172-2.261)。
- 收缩压连续变异每升高10 mm Hg,任何卒中风险HR 3.078(95%CI 2.220-4.225),缺血性卒中HR 3.051(95%CI 2.179-4.262),出血性卒中HR 3.276(95%CI 1.172-9.092),缺血事件HR 2.865(95%CI 2.042-4.011),出血事件HR 2.764(95%CI 1.524-5.016)。
- 在平均收缩压或收缩压连续变异的各四分位组内,氯吡格雷组与普拉格雷组的事件率无差异。
临床怎么用
- 卒中后长期抗血小板治疗期间应重视高血压控制,无论使用普拉格雷还是氯吡格雷。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: High blood pressure increases bleeding risk during treatment with antithrombotic medication. The association between blood pressure levels and the risk of recurrent stroke during long-term secondary stroke prevention with thienopyridines (particularly prasugrel) has not been well studied. METHODS: This was a post hoc analysis of the randomized, double-blind, multicenter PRASTRO-I trial (Comparison of Prasugrel and Clopidogrel in Japanese Patients With Ischemic Stroke-I). Patients with noncardioembolic stroke were randomly assigned (1:1) to receive prasugrel 3.75 mg/day or clopidogrel 75 mg/day for 96 to 104 weeks. Risks of any ischemic or hemorrhagic stroke, combined ischemic events, and combined bleeding events were determined based on the mean level and visit-to-visit variability, including successive variation, of systolic blood pressure (SBP) throughout the observational period. These risks were also compared between quartiles of mean SBP level and successive variation of SBP. RESULTS: A total of 3747 patients (age 62.1±8.5 years, 797 women), with a median average SBP level during the observational period of 132.5 mm Hg, were studied. All the risks of any stroke (146 events; hazard ratio, 1.318 [95% CI, 1.094-1.583] per 10-mm Hg increase), ischemic stroke (133 events, 1.219 [1.010-1.466]), hemorrhagic stroke (13 events, 3.247 [1.660-6.296]), ischemic events (142 events, 1.219 [1.020-1.466]), and bleeding events (47 events, 1.629 [1.172-2.261]) correlated with increasing mean SBP overall. Similarly, an increased risk of these events correlated with increasing successive variation of SBP (hazard ratio, 3.078 [95% CI, 2.220-4.225] per 10-mm Hg increase; 3.051 [2.179-4.262]; 3.276 [1.172-9.092]; 2.865 [2.042-4.011]; 2.764 [1.524-5.016], respectively). Event rates did not differ between the clopidogrel and prasugrel groups within each quartile of SBP or successive variation of SBP. CONCLUSIONS: Both high mean SBP level and high visit-to-visit variability in SBP were significantly associated with the risk of recurrent stroke during long-term medication with either prasugrel or clopidogrel after stroke. Control of hypertension would be important regardless of the type of antiplatelet drugs. Registration: URL: https://www.clinicaltrials.jp; Unique identifier: JapicCTI-111582.
引用
- Toyoda K, Yamagami H, Kitagawa K, et al. Blood Pressure Level and Variability During Long-Term Prasugrel or Clopidogrel Medication After Stroke: PRASTRO-I. Stroke. 2021. PMID: 33563017. doi:10.1161/STROKEAHA.120.032824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。